Claims for Patent: 8,562,981
✉ Email this page to a colleague
Summary for Patent: 8,562,981
Title: | Stable digestive enzyme compositions |
Abstract: | Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing. |
Inventor(s): | Ortenzi; Giovanni (Monza, IT), Marconi; Marco (Cinisello Balsamo, IT), Mapelli; Luigi (Milan, IT) |
Assignee: | Aptalis Pharma Limited (Wicklow, IE) |
Application Number: | 13/019,860 |
Patent Claims: | 1. A method of treating a disorder associated with digestive enzyme deficiency comprising administering to a mammal in need thereof, a pharmaceutical composition comprising: a
plurality of coated particles, the particles comprising a core coated with an enteric coating; wherein the core comprises: 68-90 wt. % of pancrelipase; the enteric coating comprises: 10-20 wt. % of at least one enteric polymer; and 4-10 wt. % of talc; wherein each wt. % is based on the total weight of the coated particles; and wherein the coated particles have a moisture content of about 3% or less, and exhibit a loss of pancrelipase activity of no more than 25% after six months of accelerated
stability testing.
2. The method of claim 1, wherein the core further comprises 1-4 wt. % of at least one disintegrant; 0.2-0.6 wt. % of at least one glidant; 2-6 wt. % of at least one polymeric binder; and 0.2-0.6 wt. % of at least one lubricant, based on the total weight of the coated particles. 3. The method of claim 2, wherein the at least one disintegrant is croscarmellose sodium, the at least one glidant is colloidal silicon dioxide, the at least one polymeric binder is microcrystalline cellulose, the at least one lubricant is magnesium stearate, and the enteric polymer is hydroxypropylmethylcellulose phthalate. 4. The method of claim 2, wherein the core further comprises 0.5-1.0 wt. % of at least one plasticizer, based on the total weight of the coated particles. 5. The method of claim 4, wherein the at least one plasticizer is hydrogenated castor oil. 6. The method of claim 1, wherein the pancrelipase is porcine derived. 7. The method of claim 1, wherein the coating further comprises 1-2 wt. % of at least one plasticizer, based on the total weight of the coated particles. 8. The method of claim 7, wherein the at least one plasticizer is triethyl citrate. 9. The method of claim 1, wherein the coated particles exhibit a loss of pancrelipase activity of no more than 15% after six months of accelerated stability testing. 10. The method of claim 1, in the form of a capsule comprised of hydroxypropylmethylcellulose, filled with said plurality of coated particles. 11. The method of claim 1, wherein the ratio of protease to lipase activity of the pancrelipase is from about 1.8-6.2. 12. The method of claim 1, wherein the ratio of protease to lipase activity of the pancrelipase is from about 2.0-6.1. 13. The method of claim 1, wherein the ratio of amylase to lipase activity of the pancrelipase is from about 1.8-8.2. 14. The method of claim 1, wherein the ratio of amylase to lipase activity of the pancrelipase is from about 2.0-8.2. 15. The method of claim 1, wherein the ratio of lipase:protease:amylase activities of the pancrelipase ranges from about 1:10:10 to about 10:1:1. |
Details for Patent 8,562,981
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | COTAZYM | pancrelipase | Capsule, Delayed Release | 020580 | December 09, 1996 | ⤷ Sign Up | 2027-02-20 |
Abbvie Inc. | CREON | pancrelipase | Capsule, Delayed Release | 020725 | April 30, 2009 | ⤷ Sign Up | 2027-02-20 |
Abbvie Inc. | CREON | pancrelipase | Capsule, Delayed Release | 020725 | June 10, 2011 | ⤷ Sign Up | 2027-02-20 |
Abbvie Inc. | CREON | pancrelipase | Capsule, Delayed Release | 020725 | March 14, 2013 | ⤷ Sign Up | 2027-02-20 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,562,981
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 200905630 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2008102264 | ⤷ Sign Up |
United States of America | 8562980 | ⤷ Sign Up |
United States of America | 8562979 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.